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Background/aim: Heat shock protein 90α (Hsp90α) is considered a tumor biomarker in many human malignancies. This study
investigated the diagnostic value of Hsp90α combined with other traditional lung cancer biomarkers (CEA, CYFRA21-1, and NSE) and
its role in monitoring the treatment response of lung cancer patients.
Materials and methods: A total of 205 patients with lung cancer and 186 patients with lung benign disease who were admitted to our
hospital were enrolled from 2018 to 2020. The 205 patients included 76 cases of squamous, 92 cases of adenocarcinoma, and 37 cases of
small cell lung cancer. There were 49 patients with TNM I+II and 156 patients with TNM III+IV. A total of 10 mL baseline peripheral
venous blood samples and subsequent peripheral venous blood samples (7 days after two cycles of chemotherapy) were collected, and
the levels of Hsp90α, carcinoembryonic antigen (CEA), Cytokeratin 19 fragments (CYFRA21-1), and neuron-specific enolase (NSE)
were detected by ELISA kit.
Results: Hsp90α was obviously higher in serum from patients with lung cancer than in patients with benign lung disease (p < 0.0001).
Moreover, Hsp90α levels were higher in patients with advanced-stage (stage III-IV) lung cancer compared to those with early-stage
(stage I-II). Hsp90α level was significantly decreased following treatment with chemotherapy in the progress partial response group
(p = 0.017), whereas the level of Hsp90α was significantly higher after chemotherapy treatment in the progressive disease group (p <
0.0001). In addition, compared with CYFRA21-1, CEA, or NSE alone, the AUC of Hsp90α combined with CYFRA21-1, CEA, or NSE
were significantly higher in the diagnosis of adenocarcinoma or small-cell lung cancer.
Conclusion: Hsp90α combined with CYFRA21-1, CEA, and NSE can be used as diagnostic indicators of lung cancer. The Hsp90α level
can be used to monitor treatment response.
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1. Introduction
Lung cancer is the most common cancer and the main
cause of cancer death worldwide. There were about 1.76
million cancer-related deaths worldwide in 2018 [1].
Although some progress has been made in immunotherapy,
molecular targeted therapy, chemotherapy, radiotherapy
and surgical treatment, the 5-year survival rate of lung
cancer is significantly low [2]. Most patients with lung
cancer are diagnosed in an advanced stage, and the
prognosis is poor. This calls for the development of
biomarkers to facilitate the early diagnosis of lung cancer.
Traditional biomarkers of lung cancer include
carcinoembryonic antigen (CEA), cytokeratin 19 fragments
(CYFRA21-1), and neuron-specific enolase (NSE). Among
them, CEA was first reported in gastrointestinal carcinoma
in 1965 and it has since been found to be upregulated
in colorectal and lung cancer [3]. CYFRA21-1 and NSE

were expressed in lung cancer and could be biomarkers of
small cell lung cancer [4,5]. Carcinoma diagnosis needs
histopathological confirmation. CEA, NSE, CYFRA21-1,
and Hsp90α were tumor markers, which can be used
as diagnostic tools. However, in order to improve the
diagnostic efficiency, multiple tumor markers are usually
detected and analyzed at the same time [3–5].
Heat shock proteins (HSPs) are a group of proteins
that respond to extreme temperature changes, infection,
inflammation, and hypoxia [6]. Hsp90, which was named
based on its molecular weight, has two isoforms, Hsp90α
and Hsp90β [7]. Hsp90α has been reported to be involved
in the occurrence, development, and metastasis of tumors.
This indicates that Hsp90α could be used as a marker
for early detection of malignancy tumors [8]. However,
the plasma Hsp90α level in lung cancer has rarely been
reported.
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Here, we measured the serum Hsp90α level in lung
cancer patients and investigated the diagnostic value of
Hsp90α combined with other traditional lung cancer
biomarkers (CEA, CYFRA21-1, and NSE) and its role in
monitoring the treatment response of lung cancer patients.
2. Materials
2.1. Participants
A total of 205 lung cancer patients and 186 benign lung
disease patients treated in the First Affiliated Hospital
of Anhui Medical University from 2018 to 2020 were
enrolled in this study. The lung cancer was confirmed by
the pathologic data of broncho-fiberscope or CT-guided
lung biopsy. Evaluation of lung cancer patients was
performed by improved tumor lymph node metastasis
(TNM) classification [9]. Lung benign disease included
pneumonia, COPD, etc. The patients were selected
according to the following criteria: (a) primary lung
cancer, (b) previously untreated, and surgery. Moreover,
patients whose cancer arose in other sites were excluded.
The study protocol was approved by the Medical
Ethics and Human Clinical Trial Committee of Anhui
Medical University. All procedures in this study involving
participants conform to the ethical standards of the agency
and/or the National Research Council, as well as the 1964
Helsinki declaration and subsequent amendments or
similar ethical standards. Informed consent was obtained
from all individual participants.
In addition, a total of 127 advanced-stage lung cancer
patients received chemotherapy, paclitaxel+carboplatin,
pemetrexed+carboplatin, and etoposide+lobaplatin.
Treatment efficacy was evaluated according to RECIST
Version 1.1 (Response Evaluation Criteria in Solid Tumors)
after the second cycle of chemotherapy [10]. Patients were
grouped into partial response (PR), progressive disease
(PD), and stable disease (SD) according to treatment
response.
2.2. Detection of serum levels of Hsp90α, CEA, NSE, and
CYFRA21-1
A total of 10 mL baseline peripheral venous blood samples
and subsequent peripheral venous blood samples (7
days after two cycles of chemotherapy) were collected
and were stored at –20 °C until use. The ELISA kits
were used to measure the levels of HSP90α (#BMS2090,
Invitrogen, USA), CEA (#A46341, Invitrogen, USA), NSE
(E-EL-H1047c, Elabscience, China), and CYFRA21-1
(EH0364, FineTest, China). Briefly, the 96-well plate is
preheated to 37 °C for 30 min. The standard and diluted
plasma samples (1:50 dilution) were loaded into 96well microplates. Gradually adding anti-Hsp90α HRPconjugated antibodies and tetramethylbenzidine (TMB)
substrate, the optical density (OD) was measured at 450
nm by spectrophotometer. The protein content of each
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sample was calculated according to the standard curve of
OD value.
2.3. Statistical analyses
The SPSS 22.0 software (SPSS Inc., Chicago, IL, USA) was
used for data analysis. The data were expressed as the median
of abnormal distribution data (p25–p75). The correlation
between Hsp90 concentration and pathological type was
evaluated by the Kruskal Wallis test. Mann Whitney test
was used to evaluate differences in Hsp90α level in relation
to other clinicopathological variables, including gender
(male vs. female), age (≥60 vs. < 60), TNM stage (I + II vs.
III + IV), and so on. The receiver operating characteristic
(ROC) curve was used to evaluate the diagnostic value
of Hsp90α in lung cancer. An area under the ROC
curve (AUC) value close to 1 represents good diagnostic
accuracy, whereas poor diagnostic accuracy is indicated by
AUC values as low as 0.5. The comparison among AUCs
was evaluated using logistic regression analysis using
MedCalc 14.8.1 (MedCalc Software bvba). The ROC curve
was generated using SPSS 22.0 package. A P-value of <0.05
was considered statistically significant.
3. Results
3.1. Basic information of participants
The 205 lung cancer patients were enrolled in this study.
There are 152 males and 53 females, whose mean age was
61.45 ± 10.52 (33–87 years). In addition, another 186
lung benign disease patients were also enrolled in this
study, including 113 males and 73 females, whose mean
age was 62.98 ± 15.01 (19–98 years). The demographic
characteristics of lung cancer and control patients are
shown in Table 1.
3.2. The Hsp90α level in patients
Compared with benign lung disease patients, the serum
level of Hsp90α (128.23 ng/mL, ranging from 76.40 to
167.20 ng/mL) in lung cancer patients was higher (p <
0.0001, Figure 1A).
We investigated the Hsp90α level in three pathological
types of lung cancer. As shown in Figures 1B, 1C, and 1D,
compared with benign lung disease patients, the Hsp90α
level was significantly higher in squamous cell carcinoma,
adenocarcinoma, and small-cell lung cancer. According
to the results of statistical analysis, we did not observe a
statistically significant difference for plasma Hsp90α levels
compared according to age, gender, three pathological cell
type, smoking status, metastasis condition except TNM
stage (Table 2).
3.3. Diagnostic value of Hsp90α in lung cancer
The 205 cases of lung cancer were divided into squamous
cell carcinoma (76 cases), adenocarcinoma (92 cases), and
small cell lung cancer (37 cases). In 76 cases of squamous
cell carcinoma, as shown in Figure 2A and Table 3, the AUC
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Table 1. The demographic characteristics of lung cancer and benign lung disease.
Group

lung cancer
(n = 205)

benign lung diseases
(n = 186)

Age (years)

61.45 ± 10.52 (33–87)

62.98 ± 15.01 (19–98)

Gender (male/female)

152/53

113/73

BMI

26.34 ± 5.54 (17.01–38.12)

24.78 ± 5.42 (16.24–36.97)

Smoking or former smoking

92

79

Diabetes mellitus

23

27

Hypertension

56

41

Chronic gastropathy

21

18

Cerebrovascular diseases

34

37

Comorbidities (cases)

Figure 1. The serum levels of Hsp90α in patients with lung cancer (A), squamous cell carcinoma (B), adenocarcinoma (C), and
small cell lung cancer (D) compared with benign lung diseases.

of Hsp90α combined with CYFRA21-1 was significantly
higher than that of CYFRA21-1 alone (0.937, 95% CI:
0.900–0.963 vs. 0.858, 95% CI: 0.809–0.898, p = 0.0049).
The PPV and NPV of biomarker combination (CYFRA21-

1+Hsp90α) were 0.913 (0.850–0.951) and 0.813 (0.752–
0.863). Meanwhile, compared with CEA or NSE alone,
the AUC of Hsp90α combined with CEA or NSE was
significantly higher in the diagnosis of adenocarcinoma
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Table 2. Relationships between the Hsp90α concentration and clinic-pathologic characteristics in
205 lung cancer patients. Data were presented as Median (P25–P75).
Items

Cases (n)

Hsp90α (ng/mL)

Male

152

129.59 (82.01–169.75)

Female

53

124.35 (62.48–156.57)

Gender

P-value
0.586

Age, year

0.926

<60

80

128.07 (79.14–160.53)

≥60

125

128.03 (70.87–169.71)

Never

113

121.39 (65.26–159.98)

Smoking or former smoking

92

136.64 (102.92–172.58)

Squamous

76

117.79 (60.17–158.79)

Adenocarcinoma

92

132.90 (91.79–170.93)

Small cell lung cancer

37

138.07 (102.47–169.02)

I+II

49

113.16 (62.81–151.81)

III+IV

156

132.97 (78.28–173.88)

Brain metastasis

21

119.61 (60.55–166.90)

Bone metastasis

11

132.03 (60.57–180.12)

Pleural metastasis

40

144.82 (104.55–197.62)

Multiple metastases

64

140.09 (107.27–168.60)

Smoking status

Pathological type

0.070
0.146

TNM stage

0.044

Metastasis condition

0.406

Figure 2. ROC curves of Hsp90α, CYFRA21-1, and the combination of these factors in the diagnosis of patients with squamous cell
carcinoma and lung benign disease (A), ROC curves of Hsp90α, CEA, and the combination of these factors in the diagnosis of patients
with carcinoma and lung benign disease (B), ROC curves of Hsp90α, NSE, and the combination of these markers in the diagnosis of
patients with small cell lung cancer and small cell lung cancer (C).

or small-cell lung cancer. The PPV and NPV of biomarker
combination (CEA+Hsp90α) were 0.813 (0.746–0.863)
and 0.946 (0.898–0.972), respectively. The PPV and NPV

750

of biomarker combination (NSE+Hsp90α) were 0.980
(0.943–0.993) and 0.970 (0.854–0.994), respectively
(Figures 2B and 2C, Table 4-5).
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Table 3. The ROC of the conjoint analysis of CYFRA21-1 and Hsp90α in lung squamous cell carcinoma.
Items

CYFRA21-1

Hsp90α

CYFRA21-1 +Hsp90α

Optimal cut-off

4.77 (ng/mL)

101.78 (ng/mL)

-

Sensitivity

0.671

0.553

0.882

Specificity

0.830

0.952

0.860

Younden’s index

0.596

0.505

0.742

SE

0.0279

0.0339

0.0516

AUC (95% CI)

0.858 (0.809–0.898)

0.787 (0.732–0.835)

0.937 (0.900–0.963)

NPV (95% CI)

-

-

0.913 (0.850–0.951)

PPV (95% CI)

-

-

0.813 (0.752–0.863)

P-value*

0.0049

<0.001

-

*Comparing the area under ROC curve of combination to single tumor marker in lung squamous cell
carcinoma vs. benign lung disease group.
Table 4. The ROC of the conjoint analysis of CEA and Hsp90α in lung adenocarcinoma.
Items

CEA

Hsp90α

CEA+Hsp90α

Optimal cut-off

5.7 (ng/mL)

114.78 (ng/mL)

-

Sensitivity

0.467

0.685

0.772

Specificity

0.929

0.973

0.957

Younden’s index

0.456

0.658

0.729

SE

0.0358

0.0255

0.0311

AUC (95% CI)

0.737 (0.681–0.788)

0.837 (0.789–0.879)

0.893 (0.851–0.927)

NPV (95% CI)

-

-

0.813 (0.746–0.863)

PPV (95% CI)

-

-

0.946 (0.898–0.972)

P-value*

<0.001

0.0095

-

*Comparing the area under ROC curve of combination to single tumor marker in lung adenocarcinoma
vs. benign lung disease group.
Table 5. The ROC of the conjoint analysis of NSE and Hsp90α in lung small cell lung cancer.
Items

NSE

Hsp90α

NSE +Hsp90α

Optimal cut-off

16.325 (ng/mL)

102.95 (ng/mL)

-

Sensitivity

0.757

0.703

0.919

Specificity

0.880

0.960

0.993

Younden’s index

0.637

0.663

0.912

SE

0.0362

0.0230

0.0116

AUC (95% CI)

0.877 (0.827–0.917)

0.945 (0.906–0.979)

0.986 (0.961–0.997)

NPV (95% CI)

-

-

0.980 (0.943–0.993)

PPV (95% CI)

-

-

0.970 (0.854–0.994)

P-value*

0.009

0.044

-

*Comparing the area under ROC curve of combination to single tumor marker in lung small cell lung
cancer vs. benign lung disease group.
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Figure 3. Patients with advanced lung cancer were grouped into PR (A), PD (B), and SD (C) according to treatment response. The serum
levels of Hsp90α were reassessed after the second cycle of chemotherapy.

3.4. The dynamic changes of Hsp90α in response to
chemotherapy
We further measured serum Hsp90α levels in 127 advanced
lung cancer patients who received chemotherapy. The
results showed that the Hsp90α level was significantly
decreased after chemotherapy in the PR group (119.48 ±
7.63 vs. 143.71 ± 6.41 ng/mL, n = 42, p = 0.017, Figure 3A).
Hsp90α level was not significantly changed after treatment
in SD group (147.12 ± 7.75 vs. 130.63 ± 9.01 ng/mL, n =
59, p = 0.168, Figure 3B). However, Hsp90α was increased
after chemotherapy treatment in the PD groups (183.31 ±
14.46 vs. 104.65 ± 13.54 ng/mL, n = 26, p < 0.000, Figure
3C).
4. Discussion
To improve the diagnosis of lung cancer, many tumor
markers, including CYFRA21-1, CEA, and NSE, have
been intensively evaluated and have been widely used in
the diagnosis of lung cancer. However, each marker has
its own specificity and sensitivity, which might lead to
limitations in the diagnosis. The combined detection of
tumor markers may be of great importance in the diagnosis
of tumors. Hsp90α has also been demonstrated to have
diagnostic value in lung cancer. In the present study, we
demonstrated that the detection of Hsp90α combined with
that of CYFRA21-1, CEA, and NSE could significantly
increase the AUC and the sensitivity.
Hsp90α is a chaperone protein that regulates protein
folding. It also helps proteins remain stable in response to
oxidative and heat stress, as well as protein degradation
processes [11]. Hsp90α is considered as a tumor marker
for the diagnosis of colorectal cancer, prostate, etc [12–
14]. As reported by Shi et al. [15], the Hsp90α level was
increased in advanced lung cancer patients. In the present
study, Hsp90α was significantly higher in patients with
lung cancer compared to those with benign lung disease.
It was also higher in advanced lung cancer (III-IV stage)
than in early-stage (I-II stage) cancer, which indicated that
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Hsp90α may play an important role in the progression of
lung cancer.
ROC analysis has been used extensively to compare the
diagnostic value of tumor markers. The AUC is considered
a quantitative measure of the discrimination power of
tumor markers in the differentiation of lung cancer cases
from benign lung diseases. CYFRA21-1, CEA, NSE, and
other tumor markers are widely used in the diagnosis
of lung cancer. As they have their own specificity and
sensitivity, hence they have different diagnostic potential.
Therefore, combining different markers may improve the
diagnostic value of individual markers [16]. In the current
study, we found that Hsp90α combined with CYFRA21-1,
CEA, and NSE can improve the diagnostic level of lung
cancer, which was consistent with the study of Shi et al.
[15]. In addition, lung cancer patients were further divided
into subgroups, squamous cell carcinoma (Table 3), lung
adenocarcinoma (Table 4), and small cell lung cancer
(Table 5). CYFRA21-1, a fragment of cytokeratin 19, is
mainly expressed in tumor cells of epithelial origin and can
be used as a marker for epithelial cancers. According to one
study, the level of CYFRA21-1 in squamous cell carcinoma
was higher than that in adenocarcinoma and SCLC [16].
In the present study, the sensitivity and specificity of
squamous cell carcinoma by CYFRA21-1 were 0.671 and
0.830, respectively. When CYFRA21-1 was combined with
Hsp90α, the sensitivity and specificity of the combination
were both increased. Meanwhile, the sensitivity and
specificity of lung adenocarcinoma by CEA were 0.467
and 0.929, respectively. When CEA was combined with
Hsp90α, the sensitivity and specificity of the combination
were also both increased. Moreover, the sensitivity and
specificity of lung adenocarcinoma by NSE were 0.757
and 0.880, respectively. When NSE was combined with
Hsp90α, the sensitivity and specificity of the combination
were also both increased. These combinations provided
good diagnostic accuracy for carcinoma and small cell
lung cancer, which suggested that Hsp90α combined with
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these markers provided a better diagnostic value for lung
cancer.
Furthermore, we assessed the value of Hsp90α in
predicting the response of patients with lung cancer to
chemotherapy. Results showed that the Hsp90α level was
higher in the PD group compared to SD and PR groups.
Consistently, Žáčková et al. demonstrated that lower
serum levels of Hsp90α in patients with chronic myeloid
leukemia were correlated with good response to therapy
[17]. Collectively, our results suggested that Hsp90α may
be used to monitor therapeutic responses in patients with
lung cancer.

Moreover, we show that Hsp90α combined with
CYFRA21-1, CEA, and NSE have a higher diagnostic
value in lung cancer. Furthermore, Hsp90α measurement
may help monitor treatment response. However, several
limitations in this study are worth mentioning, such as the
retrospective nature of the study and the small number of
patients for each lung cancer subtype.
Conﬂict of interest statement
The authors declare that there is no conflict of interest
related to this report.

References
1.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal
A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185
countries. CA: a cancer journal for clinicians 2018; 68 (6): 394424. doi: 10.3322/caac.21492

10.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent
D et al. New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). European Journal of
Cancer 2009; 45 (2): 228-247. doi: 10.1016/j.ejca.2008.10.026

2.

Mazzone P, Mekhail T. Current and emerging medical
treatments for non-small cell lung cancer: a primer for
pulmonologists. Respiratory Medicine 2012; 106 (4): 473-492.
doi: 10.1016/j.rmed.2011.10.016

11.

Jayaprakash P, Dong H, Zou M, Bhatia A, O’Brien K et al.
Hsp90α and Hsp90β together operate a hypoxia and nutrient
paucity stress-response mechanism during wound healing.
Journal of Cell Science 2015; 128 (8): 1475-1480. doi: 10.1242/
jcs.166363

3.

Gold P, Freedman SO. Demonstration of tumor-specific
antigens in human colon carcinoma by immunological
tolerance and absorption techniques. Journal of Experimental
Medicine 1965; 121 (3): 439-462. doi: 10.1084/jem.121.3.439

12.

Devarakonda CV, Kita D, Phoenix KN, Claffey KP. Patientderived heavy chain antibody targets cell surface HSP90
on breast tumors. BMC Cancer 2015; 15: 614. doi: 10.1186/
s12885-015-1608-z

4.

Chiu NF, Yang HT. High-sensitivity detection of the lung cancer
biomarker CYFRA21-1 in serum samples using a CarboxylMoS(2) functional film for SPR-based immunosensors.
Frontiers in Bioengineering and Biotechnology 2020; 8: 234.
doi: 10.3389/fbioe.2020.00234

13.

Hance MW, Dole K, Gopal U, Bohonowych JE, JezierskaDrutel A et al. Secreted Hsp90 is a novel regulator of the
epithelial to mesenchymal transition (EMT) in prostate cancer.
Journal of Biological Chemistry 2012; 287 (45): 37732-37744.
doi: 10.1074/jbc.M112.389015

5.

Genet S, Visser E, van den Borne B, Soud MY, Belderbos HNA
et al. Correction of the NSE concentration in hemolyzed serum
samples improves its diagnostic accuracy in small-cell lung
cancer. Oncotarget 2020; 11 (27): 2660-2668. doi: 10.18632/
oncotarget.27664

14.

Nagaraju GP, Long TE, Park W, Landry JC, TaliaferroSmith L et al. Heat shock protein 90 promotes epithelial to
mesenchymal transition, invasion, and migration in colorectal
cancer. Molecular Carcinogenesis 2015; 54 (10): 1147-1158.
doi: 10.1002/mc.22185

6.

Wong DS, Jay DG. Emerging roles of extracellular Hsp90 in
cancer. Advances in Cancer Research 2016; 129: 141-163. doi:
10.1016/bs.acr.2016.01.001

15.

7.

Li J, Buchner J. Structure, function and regulation of the hsp90
machinery. Biomedical Journal 2013; 36 (3): 106-117. doi:
10.4103/2319-4170.113230

Shi Y, Liu X, Lou J, Han X, Zhang L et al. Plasma levels of heat
shock protein 90 alpha associated with lung cancer development
and treatment responses. Clinical Cancer Ressearch 2014; 20
(23): 6016-6022. doi: 10.1158/1078-0432.CCR-14-0174

16.

Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with
CEA, CYFRA21-1 and NSE improved its diagnostic value
for lung cancer. Life Science 2018; 194: 1-6. doi: 10.1016/j.
lfs.2017.12.020

17.

Záčková M, Moučková D, Lopotová T, Ondráčková Z, Klamová
H, Moravcová J. Hsp90 - a potential prognostic marker in
CML. Blood Cells Molecules and Disease 2013; 50 (3): 184189. doi: 10.1016/j.bcmd.2012.11.002

8.

9.

Schwartz H, Scroggins B, Zuehlke A, Kijima T, Beebe K et al.
Combined HSP90 and kinase inhibitor therapy: insights from
the cancer genome atlas. Cell Stress & Chaperones 2015; 20 (5):
729-741. doi: 10.1007/s12192-015-0604-1
Abdel-Rahman O. Validation of the AJCC 8th lung cancer
staging system among patients with small cell lung cancer.
Clinical & Translational Oncology 2018; 20 (4): 550-556. doi:
10.1007/s12094-017-1739-6

753

